We are delighted to have been confirmed as one of the companies approved for DTIF grant funding this year.

This is awarded to projects that have the innovative potential to disrupt markets. CrannMed and our partners, the Institute of Clinical Trials (University of Galway) and Synecco Ltd, are one of only 12 projects to be awarded funding in this year’s call. The money will be used to accelerate the development of our next generation embolics for the treatment of chronic inflammatory conditions.